Soligenix Inc
SNGX3.110USD
+0.370+13.50%
收盤 08/04, 16:00（美東）報價延遲15分鐘
9.90M總市值
虧損本益比TTM
關於 Soligenix Inc 公司
Soligenix, Inc. 是一家後期生物製藥公司，專注於開發和商業化用於治療罕見疾病的產品，這些疾病存在未滿足的醫療需求。其專業生物治療部門正在開發並專注於 HyBryte（擬定名稱爲 SGX301）的商業化，這是一種新型光動力療法 (PDT)，利用安全的可見光激活局部合成金絲桃素來治療皮膚 T 細胞淋巴瘤 (CTCL)。該部門的開發計劃還包括將合成金絲桃素 (SGX302) 擴展到牛皮癬和將 dusquetide (SGX942 和 SGX945) 擴展到治療炎症性疾病。其公共衛生解決方案部門包括 RiVax（其蓖麻毒素候選疫苗）和 SGX943（其抗生素耐藥性和新發傳染病治療候選藥物）的開發計劃以及針對絲狀病毒（如馬爾堡和埃博拉）的疫苗計劃和 CiVax（其用於預防 COVID-19 的候選疫苗）。
公司簡介
公司代碼SNGX
公司名稱Soligenix Inc
上市日期Apr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
員工數量14
證券類型Ordinary Share
年結日Apr 04
公司地址29 Emmons Drive
城市PRINCETON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編08540
電話16095388200
網址https://www.soligenix.com/
公司代碼SNGX
上市日期Apr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
持股股東
持股股東
佔比
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
股東類型
持股股東
佔比
Hedge Fund
3.11%
Investment Advisor/Hedge Fund
0.90%
Investment Advisor
0.54%
Individual Investor
0.02%
Other
95.43%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
50
149.55K
4.58%
-122.83K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
2023Q1
62
7.29K
3.99%
-8.64K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Connective Capital Management, LLC
101.63K
3.11%
+101.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
29.37K
0.9%
+3.27K
+12.55%
Mar 31, 2025
UBS Financial Services, Inc.
10.47K
0.32%
+10.16K
+3244.73%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.59K
0.11%
-1.00
-0.03%
Mar 31, 2025
The Vanguard Group, Inc.
3.18K
0.1%
--
--
May 31, 2025
Schaber (Christopher J)
379.00
0.01%
--
--
Apr 21, 2025
Plante Moran Financial Advisors, LLC
300.00
0.01%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
223.00
0.01%
--
--
Mar 31, 2025
Zeldis (Jerome B)
96.00
0%
--
--
Apr 21, 2025
Northern Trust Investments, Inc.
72.00
0%
+72.00
--
Dec 31, 2023
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
公告日期
類型
比率
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
